The paper represents clinical guidelines on frailty, developed by Russian Association of gerontologists and geriatricians. The guidelines are dedicated to geriatricians, internal medicine specialists, general practitioners, family doctors and other specialists, dealing with adult patients. The paper includes screening and diagnostic tools and treatment options for patients with frailty, along with prevention, rehabilitation and medical care organization in this cohort of patients.

The paper represents clinical guidelines on frailty, developed by Russian Association of gerontologists and geriatricians. The guidelines are dedicated to geriatricians, internal medicine specialists, general practitioners, family doctors and other specialists, dealing with adult patients. This publication includes treatment options for patients with frailty.

Memantine is a reversible N-methyl-D-a spartate (NMDA) receptor blocker. The paper reports the results of an investigation aimed at the assessment of memantine effectiveness, safety and tolerability in patients with non-dementia cognitive impairment. Two hundred and forty (240) patients were enrolled in this open-label, comparative, multicentre study. In these subjects cognitive disorders were less severe than dementia (MMSE score made up 22—27). Mean age was 69.2 + 5.7 years old. Among them 148 patients received acatinol memantine at a dosage of 20 mg daily within 6 months and 92 subjects comprised a comparison group. Memantine administration resulted in decreased severity of cognitive impairment, first of all due to the improvement of dysregulatory, mnestic and visual-spatial disorders. Besides, the treatment caused the alleviation of emotional disturbances. The degree of therapeutic effectiveness was independent from the presence or lack of cardiovascular diseases in the examined population. Further double-blind studies aimed at the assessment of memantine effectiveness in patients with non-dementia cognitive impairment are necessary.